Change in Director / Key Managerial Personnel
Nature of change: Appointment of Chief Executive Officer for Gland Pharma International Pte. Ltd (Wholly-owned subsidiary of Gland Pharma Limited)
Name and details: Mr. Ajay Sahni has been appointed as the Chief Executive Officer of Gland Pharma International Pte. Ltd. ('Gland Singapore'), effective November 2, 2026.
Responsibilities: Mr. Sahni will be responsible for Cenexi business, a wholly owned step-down subsidiary of Gland Pharma Limited, and shall be reporting to the CEO of Gland Pharma Limited.
Brief profile and qualifications: Mr. Ajay Sahni has over 36 years of experience in FMCG & Pharmaceutical industries, specializing in financial management, business development and general management. His extensive experience includes roles as Finance Director, Project Manager-Business Development, Director (Financial Control, Planning and Analysis), Regional Finance Director for South and South-East Asia, President, and Managing Director in various companies including Sanofi SA, Sanofi Synthelabo Inc., Sanofi-Synthelabo Pte. Ltd, Ferring Pharmaceuticals, Wockhardt France SAS and multiple subsidiaries including Laboratoires Negma SAS, Wockhardt Bio AG, and Pinewood Healthcare Ltd. He has worked in France, Belgium, Ireland, Switzerland, Singapore, and USA. In previous leadership roles, he was Managing Director for Pinewood Healthcare Ltd, Ireland; Managing Director for Wockhardt Bio AG, Switzerland; President of Wockhardt France SAS and its subsidiaries. Mr. Ajay holds a Bachelor's degree in Business Administration from European University of Brussels, Belgium.
Relationship with other directors: Not Applicable
Regulatory compliance: The appointment complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure also references compliance with BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE Circular ref. no. NSE/CML/2018/24, both dated June 20, 2018.
Key Financial or Operational Approvals
No financial or operational approvals were mentioned in this disclosure.
Strategic or Business Context
Mr. Sahni's appointment to lead the Singapore subsidiary and oversee the Cenexi business indicates continued international expansion and focus on subsidiary management within Gland Pharma's corporate structure. His extensive international experience across multiple countries suggests a strategic emphasis on global operations management.
Any Other Material Information
Company details: Gland Pharma Limited is located at Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India.
Contact information: Tel: +91-40-30510999, Fax: +91 0-30510800
Company representatives: Pallerlamudi Sampath Kumar serves as Company Secretary and Compliance Officer.
Stock information: Scrip Code: 543245 (BSE), Symbol: GLAND (NSE), ISIN: INE068V01023